Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients? (GREAT)
This study is ongoing, but not recruiting participants.
Psychiatric Centre Rigshospitalet
University Hospital, Gentofte, Copenhagen
University of Cambridge
Information provided by (Responsible Party):
Anders Fink-Jensen, MD, DMSci, Psychiatric Centre Rigshospitalet
First received: April 14, 2013
Last updated: May 4, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||March 2017|
|Primary Completion Date:||March 2016 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Sharma AN, Ligade SS, Sharma JN, Shukla P, Elased KM, Lucot JB. GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats. Metab Brain Dis. 2015 Apr;30(2):519-27. doi: 10.1007/s11011-014-9591-7.
Larsen JR, Vedtofte L, Holst JJ, Oturai P, Kjær A, Correll CU, Vilsbøll T, Fink-Jensen A. Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial. BMJ Open. 2014 Mar 25;4(3):e004227. doi: 10.1136/bmjopen-2013-004227. Erratum in: BMJ Open. 2015;5(5):e004227corr1. Corell, Christoph U [corrected to Correll, Christoph U].